ketoconazole hra
hra pharma rare diseases - ketoconazole - cushing syndrome - antimykotika for systemisk bruk - ketokonazol hra er indisert for behandling av endogent cushings syndrom hos voksne og ungdom over 12 år.
canizol vet 200 mg
dechra regulatory b.v. - ketokonazol - tablett med smak - 200 mg
fungoral 20 mg/ ml
karo pharma ab (1) - ketokonazol - sjampo - 20 mg/ ml
fungoral 20 mg/ g
karo pharma ab (1) - ketokonazol - krem - 20 mg/ g
canizol vet 400 mg
le vet beheer b.v. - ketokonazol - tablett med smak - 400 mg
onduarp
boehringer ingelheim international gmbh - telmisartan - hypertensjon - sirkulasjonssystem - behandling av essensiell hypertensjon hos voksne:legg på therapyonduarp er indisert hos voksne hvis blodtrykket ikke er tilstrekkelig kontrollert på amlodipine. erstatning therapyadult pasienter som mottar telmisartan og amlodipine fra separate tabletter kan i stedet få tabletter av onduarp inneholder den samme komponenten doser.
onglyza
astrazeneca ab - saxagliptin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
entocort 2 mg/100 ml
tillotts pharma gmbh - budesonid - tablett og væske til rektalvæske, suspensjon - 2 mg/100 ml
vesicare 5 mg
astellas pharma - kastrup - solifenacinsuksinat - tablett, filmdrasjert - 5 mg